1
|
Casas ML, Esteban Á, González-Muñoz M, Labrador-Horrillo M, Pascal M, Teniente-Serra A. Proyecto VALIDA: Validation of ALlergy In vitro Diagnostics Assays (Herramientas y recomendaciones para la valoración de las pruebas in vitro en el diagnóstico de la alergia). ADVANCES IN LABORATORY MEDICINE 2020; 1:20200022. [PMCID: PMC10197503 DOI: 10.1515/almed-2020-0022] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Accepted: 05/05/2020] [Indexed: 08/29/2023]
Abstract
En la evaluación del paciente con sospecha de alergia las pruebas de detección y cuantificación de la inmunoglobulina E (IgE) específica in vitro se usan de manera habitual en los laboratorios clínicos para ayudar en el diagnóstico de la alergia. Actualmente existen diferentes alternativas comerciales para realizar estos ensayos, pero los resultados obtenidos por cada uno de ellos pueden variar, lo que condiciona el diagnóstico y el tratamiento que se le proporcionará al paciente. Con el fin de dar respuesta a los retos planteados por las diferencias entre las distintas técnicas para la determinación in vitro de la IgE específica, un grupo de expertos ha recogido en un documento una serie de recomendaciones sobre las implicaciones que puede tener el uso de una determinada técnica in vitro y el impacto en el manejo del paciente alérgico que suponen las diferencias entre las distintas técnicas. La lectura y el análisis de este documento de consenso ayudarán a entender las implicaciones que tiene el cambio de método de diagnóstico in vitro en el manejo del paciente con alergia, en su calidad de vida y en los costes socioeconómicos asociados a la enfermedad.
Collapse
Affiliation(s)
- María L. Casas
- Sociedad Española de Medicina de Laboratorio (SEQC-ML), Barcelona, España
- Servicio de Análisis Clínicos, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España
| | - Ángel Esteban
- Sociedad Española de Medicina de Laboratorio (SEQC-ML), Barcelona, España
- Servicio de Análisis Clínicos, Hospital General Universitario de Alicante, Alicante, España
| | - Miguel González-Muñoz
- Sociedad Española de Inmunología (SEI), Barcelona, España
- Servicio de Inmunología, Hospital Universitario La Paz, Madrid, España
| | - Moisés Labrador-Horrillo
- Sociedad Española de Alergología e Inmunología Clínica (SEAIC), Madrid, España
- Servicio de Alergología, Hospital Universitari Vall d’Hebron, Barcelona, España
| | - Mariona Pascal
- Servicio de Alergología, Hospital Universitari Vall d’Hebron, Barcelona, España
- Servicio de Inmunología, CDB, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, España
- Red de Investigación ARADyAL, Instituto Carlos III, Madrid, España
| | - Aina Teniente-Serra
- Sociedad Española de Inmunología (SEI), Barcelona, España
- Servicio de Inmunología, LCMN, Hospital Universitari Germans Trias i Pujol, Badalona, España
| |
Collapse
|
2
|
Casas ML, Esteban Á, González-Muñoz M, Labrador-Horrillo M, Pascal M, Teniente-Serra A. VALIDA project: Validation of allergy in vitro diagnostics assays (Tools and recommendations for the assessment of in vitro tests in the diagnosis of allergy). ADVANCES IN LABORATORY MEDICINE 2020; 1:20200051. [PMID: 37360620 PMCID: PMC10197418 DOI: 10.1515/almed-2020-0051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/20/2020] [Accepted: 05/05/2020] [Indexed: 06/28/2023]
Abstract
In vitro allergen-specific immunoglobulin E (IgE) detection and quantification tests are routinely performed in clinical laboratories to diagnose patients with a suspected allergy. Numerous commercial assays are available to test for allergies, but the results can vary widely, thereby influencing both diagnosis and treatment. Given the challenges posed by differences in the various assays for in vitro determination of specific IgE, a group of experts has compiled in a document a series of recommendations on the implications that the use of a certain in vitro technique may have and the impact on the management of the allergic patient that the differences between the various techniques represent. The reading and analysis of this consensus document will help to understand the implications of the change of in vitro diagnostic method in the management of the patient with allergy, in the quality of life and in the socioeconomic costs associated with the disease.
Collapse
Affiliation(s)
- María L. Casas
- Clinical Analysis Service, Fundación Alcorcón University Hospital, Alcorcón, Madrid, Spain
- Spanish Society of Laboratory Medicine (SEQC-ML), Barcelona, Spain
| | - Ángel Esteban
- Spanish Society of Laboratory Medicine (SEQC-ML), Barcelona, Spain
- Clinical Analysis Service, University General Hospital of Alicante, Alicante, Spain
| | - Miguel González-Muñoz
- Immunology Service, La Paz University Hospital, Madrid, Spain
- Spanish Society of Immunology (SEI), Barcelona, Spain
| | - Moisés Labrador-Horrillo
- Allergology Service, Vall d’Hebron University Hospital, Barcelona, Spain
- Spanish Society of Allergology and Clinical Immunology (SEAIC), Madrid, Spain
| | - Mariona Pascal
- Spanish Society of Immunology (SEI), Barcelona, Spain
- Spanish Society of Allergology and Clinical Immunology (SEAIC), Madrid, Spain
- Immunology Service, CBD, Hospital Clínic de Barcelona, IDIBAPS, Universitat de Barcelona, Barcelona, Spain
- ARADyAL Research Network, Carlos III Institute, Madrid, Spain
| | - Aina Teniente-Serra
- Spanish Society of Immunology (SEI), Barcelona, Spain
- Immunology Service, LCMN, Germans Trias i Pujol University Hospital, Badalona, Spain
| |
Collapse
|
3
|
Marcellusi A, Fabiano G, Viti R, Francesa Morel PC, Nicolò G, Siracusano A, Mennini FS. Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis. BMJ Open 2018; 8:e018359. [PMID: 29439067 PMCID: PMC5829672 DOI: 10.1136/bmjopen-2017-018359] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2017] [Revised: 09/07/2017] [Accepted: 12/08/2017] [Indexed: 01/24/2023] Open
Abstract
OBJECTIVES Schizophrenia is a chronic, debilitating psychiatric disease with highly variable treatment pathways and consequent economic impacts on resource utilisation. The aim of the study was to estimate the economic burden of schizophrenia in Italy for both the societal and Italian National Healthcare perspective. METHODS A probabilistic cost of illness model was applied. A systematic literature review was carried out to identify epidemiological and economic data. Direct costs were calculated in terms of drugs, hospitalisations, specialist services, residential and semiresidential facilities. Indirect costs were calculated on the basis of patients' and caregivers' loss of productivity. In addition, the impact of disability compensation was taken into account using a database from the Italian National Social Security Institute -Italy (INPS). RESULTS Overall, 303 913 prevalent patients with schizophrenia were estimated. Of these, 212 739 (70%) were diagnosed and 175 382 (82%) were treated with antipsychotics. The total economic burden was estimated at €2.7 billion (95% CI €1771.93 to €3988.65), 50.5% due to indirect costs and 49.5% to direct costs. Drugs corresponded to 10% of direct costs and hospitalisations (including residential and semiresidential facilities) accounted for 81%. CONCLUSIONS This study highlighted that indirect costs and hospitalisations (including residential and semiresidential facilities) play a major role within the expenses associated with schizophrenia in Italy, and this may be considered as a tool for public decision-makers.
Collapse
Affiliation(s)
- Andrea Marcellusi
- Economic Evaluation and HTA (EEHTA), CEIS University of Rome “Tor Vergata”, Rome, Italy
- Institute for Leadership and Management in Health, Kingston University London, London, UK
- National Research Council (CNR), Institute for Research on Population and Social Policies (IRPPS), Rome, Italy
| | - Gianluca Fabiano
- Economic Evaluation and HTA (EEHTA), CEIS University of Rome “Tor Vergata”, Rome, Italy
- Institute for Leadership and Management in Health, Kingston University London, London, UK
| | - Raffaella Viti
- Economic Evaluation and HTA (EEHTA), CEIS University of Rome “Tor Vergata”, Rome, Italy
| | | | - Giuseppe Nicolò
- Department Salute Mentale e dipendenze patologiche, ASL Roma, Rome, Italy
| | - Alberto Siracusano
- Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy
- Psychiatry and Clinical Psychology Unit, Department of Neurosciences, Fondazione Policlinico “Tor Vergata”, Rome, Italy
| | - Francesco Saverio Mennini
- Economic Evaluation and HTA (EEHTA), CEIS University of Rome “Tor Vergata”, Rome, Italy
- Institute for Leadership and Management in Health, Kingston University London, London, UK
| |
Collapse
|
4
|
Ravasio R, Girolomoni G, Gorla R. Analisi di budget impact del biosimilare di etanercept: lo scenario italiano. GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT 2018. [DOI: 10.1177/2284240318766804] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
5
|
Viola A, Costantino G, Privitera AC, Bossa F, Lauria A, Grossi L, Principi MB, Della Valle N, Cappello M. Clinical and economic impact of infliximab one-hour infusion protocol in patients with inflammatory bowel diseases: A multicenter study. World J Gastrointest Pharmacol Ther 2017; 8:131-136. [PMID: 28533923 PMCID: PMC5421112 DOI: 10.4292/wjgpt.v8.i2.131] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2016] [Revised: 12/30/2016] [Accepted: 01/16/2017] [Indexed: 02/06/2023] Open
Abstract
AIM To assess the impact of short infliximab (IFX) infusion on hospital resource utilization and costs. METHODS All inflammatory bowel diseases (IBD) patients who received IFX 1 h infusion from March 2007 to September 2014 in eight centers from Southern Italy were included in the analysis. Demographic, clinical and infusion related data were collected. The potential benefits related to the short infusion protocol were assessed both in terms of time saving and increased infusion unit capacity. In addition, indirect patient-related cost savings were evaluated. RESULTS One hundred and twenty-five patients were recruited (64 with ulcerative colitis and 61 with Crohn's disease). Median duration of disease was of 53 mo and mean age of pts at diagnosis was of 34 years (SD: ± 13). Adverse infusion reactions were reported in less than 4% both before and after short infusion. The total number of infusions across the selected centers was of 2501 (30.5% short infusions). In the analyzed cohort, 1143 h were saved (762 in the infusion and 381 in observation phases) through the rapid IFX infusion protocol. This time saving (-15% compared to the standard protocol in infusion phase) represents, from the hospital perspective, an opportunity to optimize infusion unit capacity by allocating the saved time in alternative cost-effective treatments. This is the case of opportunity cost that represents the value of forgone benefit which could be obtained from a resource in its next-best alternative use. Hence, an extra hour of infusion in the case of standard 2-h IFX represents a loss in opportunity to provide other cost effective services. The analysis showed that the short infusion increased the infusion units capacity up to 50% on days when the IFX infusions were scheduled (infusion phase). Furthermore, the analysis showed that the short IFX infusion protocol leads to time savings also in the post-infusion phase (observation) leading to a time saving of 10% on average among the analyzed centers. Finally, the short infusion protocol has been demonstrated to lead to indirect cost savings of €138/patient (average -€17.300 on the whole cohort). CONCLUSION A short IFX infusion protocol can be considered time and cost saving in comparison to the standard infusion protocol both from the hospital's perspective, as it contributes to increase infusion units capacity, and the patients' perspective, as it reduces indirect costs and the impact of treatment on everyday life and work productivity.
Collapse
|
6
|
Mennini FS, Marcellusi A, Gitto L, Iannone F. Economic Burden of Rheumatoid Arthritis in Italy: Possible Consequences on Anti-Citrullinated Protein Antibody-Positive Patients. Clin Drug Investig 2017; 37:375-386. [PMID: 28074337 DOI: 10.1007/s40261-016-0491-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
BACKGROUND Rheumatoid arthritis (RA) is an autoimmune disease with a substantial medical and economic burden. In Italy, it affects approximately 280,000 people, therefore representing the musculoskeletal disease with the highest economic impact in terms of costs for the National Health Service and the social security system. OBJECTIVE The aim of this study was to estimate the annual economic burden of RA in Italy and determine the potential cost reduction considering the most effective biologic treatment for early rapidly progressing RA (ERPRA) patients. METHODS The model developed considers both direct costs that are mainly due to the pharmacological treatments, and indirect costs, which also include the productivity lost because of the disease. A systematic literature review provided the epidemiological and economic data used to inform the model. A one-way probabilistic sensitivity analysis based on 5000 Monte Carlo simulations was performed. Furthermore, specific scenario analyses were developed for those patients presenting an ERPRA, with the aim of evaluating the effectiveness of different biologic treatments for this subgroup of patients and estimating potential cost reduction. RESULTS The total economic burden associated with RA was estimated to be €2.0 billion per year (95% confidence interval [CI] €1.8-2.3 billion). Forty-five percent of the expenditure was due to indirect costs (95% CI €0.8-1.0 billion); 45% depended on direct medical costs (95% CI €0.7-1.1 billion), and the residual 10% was determined by direct non-medical costs (95% CI €0.16-0.25 billion). In particular, the costs estimated for ERPRA patients totalled €76,171,181, of which approximately €18 million was associated with patients with a high level of anti-citrullinated protein antibodies (ACPA). The results of the analysis outline how it is possible to obtain a cost reduction for ERPRA patients of between €1 and €3 million by varying the number of patients with a high level of immunoglobulin G treated with the most effective biologic drug. In fact, the latter may determine higher efficacy outcomes, especially for poor prognostic ERPRA patients, ensuing higher levels of productivity. CONCLUSIONS This study presents a pioneering approach to estimate the direct and indirect costs of RA. The model developed is a useful tool for policy makers as it allows to understand the economic implications of RA treatment in Italy, identify the most effective allocation of resources, and select the most appropriate treatment for ERPRA patients.
Collapse
Affiliation(s)
- Francesco Saverio Mennini
- Economic Evaluation and HTA (EEHTA) CEIS, Faculty of Economics, University of Rome "Tor Vergata", Rome, Italy
- Institute for Leadership and Management in Health, Kingston University London, London, UK
| | - Andrea Marcellusi
- Economic Evaluation and HTA (EEHTA) CEIS, Faculty of Economics, University of Rome "Tor Vergata", Rome, Italy.
- Institute for Leadership and Management in Health, Kingston University London, London, UK.
- National Research Council (CNR), Institute for Research on Population and Social Policies (IRPPS), Rome, Italy.
| | - Lara Gitto
- Economic Evaluation and HTA (EEHTA) CEIS, Faculty of Economics, University of Rome "Tor Vergata", Rome, Italy
| | | |
Collapse
|
7
|
Analisi di Farmacoutilizzazione dei Trattamenti Biologici Nelle Malattie Infiammatorie Immunomediate Croniche: I Risultati di Uno Studio Osservazionale Retrospettivo Condotto in un Centro Ospedaliero del Centro Italia. GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT 2017. [DOI: 10.5301/grhta.5000271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Budget impact analysis of infliximab biosimilar: the Italian scenery. GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT 2015. [DOI: 10.5301/grhta.5000194] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
|